Provided by Tiger Trade Technology Pte. Ltd.

Voya Global Advantage and Premium Opportunity Fund

9.95
+0.12001.22%
Post-market: 9.950.00000.00%16:10 EST
Volume:92.84K
Turnover:919.01K
Market Cap:152.65M
PE:8.48
High:9.98
Open:9.85
Low:9.83
Close:9.83
52wk High:10.12
52wk Low:8.43
Shares:15.34M
Float Shares:15.34M
Volume Ratio:1.49
T/O Rate:0.61%
Dividend:1.02
Dividend Rate:10.25%
EPS(TTM):1.17
EPS(LYR):1.50
ROE:11.29%
ROA:1.29%
PB:0.95
PE(LYR):6.63

Loading ...

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

GlobeNewswire
·
Feb 06

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

GlobeNewswire
·
Feb 02

Voya Financial Inc. announces $0.085 per share monthly distribution for Voya Global Advantage and Premium Opportunity Fund

Reuters
·
Dec 16, 2025

Press Release: Saviynt Raises $700M at Approximately $3B Valuation in KKR-Led Round to Establish Identity Security as the Foundation for the AI Era

Dow Jones
·
Dec 09, 2025

Voya Financial Inc. announces $0.085 per share dividend for Voya Global Advantage and Premium Opportunity Fund

Reuters
·
Nov 18, 2025

Press Release: Voya Global Advantage and Premium Opportunity Fund & Voya Infrastructure, Industrials and Materials Fund Announces Payment of Monthly Distribution

Dow Jones
·
Nov 18, 2025

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

GlobeNewswire
·
Nov 04, 2025

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

GlobeNewswire
·
Oct 30, 2025

Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study

GlobeNewswire
·
Oct 28, 2025

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

GlobeNewswire
·
Oct 24, 2025

Press Release: Voya Equity Closed End Funds Declare Distributions

Dow Jones
·
Oct 16, 2025

Bitcoin Depot and IGA Partner to Bring Bitcoin Access to Neighborhood Grocery Stores

GlobeNewswire
·
Oct 14, 2025

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

GlobeNewswire
·
Sep 17, 2025

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

GlobeNewswire
·
Sep 17, 2025

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

Dow Jones
·
Sep 16, 2025

Voya Global Advantage & Premium Opportunity Fund Files Initial Beneficial Ownership Statement; Mark R. Wetzel Named as Director

Reuters
·
Sep 11, 2025

Press Release: Voya Equity Closed End Funds Declare Distributions

Dow Jones
·
Aug 16, 2025

Voya Financial Inc. Announces New Dividend; Voya Global Advantage and Premium Opportunity Fund to Pay $0.085 Per Share, Voya Infrastructure, Industrials and Materials Fund to Pay $0.100 Per Share

Reuters
·
Aug 16, 2025

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

Dow Jones
·
Aug 16, 2025